[go: up one dir, main page]

AR043159A1 - Moleculas de anticuerpos que tienen especificidad para il-1beta humana - Google Patents

Moleculas de anticuerpos que tienen especificidad para il-1beta humana

Info

Publication number
AR043159A1
AR043159A1 ARP040100431A ARP040100431A AR043159A1 AR 043159 A1 AR043159 A1 AR 043159A1 AR P040100431 A ARP040100431 A AR P040100431A AR P040100431 A ARP040100431 A AR P040100431A AR 043159 A1 AR043159 A1 AR 043159A1
Authority
AR
Argentina
Prior art keywords
cdr
1beta
specificity
human
antibody molecules
Prior art date
Application number
ARP040100431A
Other languages
English (en)
Inventor
Andrew George Popplewell
Alastair David Griffiths Lawson
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of AR043159A1 publication Critical patent/AR043159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)

Abstract

Molécula de anticuerpo que tiene especificidad para determinantes antigénicos de IL-1beta, usos terapéuticos de la molécula de anticuerpo y métodos para producir dicha molécula de anticuerpo. Reivindicación 1: Un anticuerpo neutralizante que tiene especificidad para IL-1beta humana que comprende una cadena pesada, en el cual el dominio variable de la cadena pesada comprende al menos una de una CDR que tiene la secuencia dad en SEQ ID NO: 5 para CDR-H1, una CDR que tiene la secuencia dada en SEQ ID NO: 6 para CDR-H2 y una CDR que tiene la secuencia dada en SEQ ID NO: 7 para CDR-H3.
ARP040100431A 2003-02-13 2004-02-12 Moleculas de anticuerpos que tienen especificidad para il-1beta humana AR043159A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303337.0A GB0303337D0 (en) 2003-02-13 2003-02-13 Biological products

Publications (1)

Publication Number Publication Date
AR043159A1 true AR043159A1 (es) 2005-07-20

Family

ID=9952969

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100431A AR043159A1 (es) 2003-02-13 2004-02-12 Moleculas de anticuerpos que tienen especificidad para il-1beta humana

Country Status (26)

Country Link
US (2) US7608694B2 (es)
EP (2) EP1597282B1 (es)
JP (2) JP4668896B2 (es)
KR (1) KR20050099509A (es)
CN (1) CN1745103A (es)
AR (1) AR043159A1 (es)
AT (1) ATE525397T1 (es)
AU (1) AU2004210776B2 (es)
BR (1) BRPI0407233A (es)
CA (1) CA2515474C (es)
CL (1) CL2004000259A1 (es)
CY (1) CY1112507T1 (es)
DK (1) DK1597282T3 (es)
EA (1) EA200501286A1 (es)
EC (1) ECSP056014A (es)
ES (1) ES2373953T3 (es)
GB (1) GB0303337D0 (es)
IS (1) IS8013A (es)
MX (1) MXPA05007392A (es)
NO (1) NO20054223L (es)
PE (1) PE20040947A1 (es)
PL (1) PL378412A1 (es)
PT (1) PT1597282E (es)
SI (1) SI1597282T1 (es)
TW (1) TW200505942A (es)
WO (1) WO2004072116A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
SI2163562T1 (sl) 2005-06-21 2014-01-31 Xoma (Us) Llc IL-1 beta vezavna protitelesa in njihovi fragmenti
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
DK2848258T3 (en) * 2005-10-26 2018-03-19 Novartis Ag Treatment of familial Mediterranean fever with anti-IL-1beta antibodies
SI1960430T1 (sl) 2005-12-09 2015-01-30 Ucb Pharma, S.A. Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
JP5645409B2 (ja) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
ES2713859T3 (es) 2007-03-22 2019-05-24 Biogen Ma Inc Proteínas de unión, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen específicamente a CD154 y usos de los mismos
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
PL2796466T3 (pl) 2007-12-07 2018-04-30 Zymogenetics, Inc. Humanizowane cząsteczki przeciwciała swoiste dla il-31
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
AU2009243184B2 (en) * 2008-04-28 2015-06-04 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
WO2010028275A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
EP2398498B1 (en) 2009-02-17 2018-09-05 UCB Biopharma SPRL Antibody molecules having specificity for human ox40
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2011036454A1 (en) 2009-09-24 2011-03-31 Ucb Pharma S.A. Bacterial host strain
RU2012119788A (ru) * 2009-10-15 2013-11-20 Эбботт Лэборетриз Связывающие il-1 белки
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
JP5904645B2 (ja) 2010-05-07 2016-04-13 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連病態の治療のための方法
BR122014011544A2 (pt) 2010-05-14 2019-08-13 Abbvie Inc proteínas de ligação à il-1
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
MY162790A (en) 2011-01-14 2017-07-14 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
SI2731973T1 (en) 2011-07-13 2018-04-30 Ucb Biopharma Aprl A bacterial host strain expressing a recombinant DSBC
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
WO2013122544A2 (en) 2012-02-13 2013-08-22 Agency For Science, Technology And Research IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
CA2936721C (en) 2014-01-20 2021-12-14 Eveon Process for reconstitution of a solid form of a pharmaceutical composition
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
US9560393B2 (en) * 2015-02-20 2017-01-31 Disney Enterprises, Inc. Media processing node
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
US11492396B2 (en) 2015-10-27 2022-11-08 UCB Biopharma SRL Methods of treatment using anti-IL-17A/F antibodies
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
US11976115B2 (en) * 2018-11-07 2024-05-07 Zeda Biopharmaceuticals, Inc. Antibody binding to human IL-1β, preparation method therefor and use thereof
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
AR125581A1 (es) 2020-12-07 2023-08-02 UCB Biopharma SRL Anticuerpos multiespecíficos y combinaciones de anticuerpos
AU2021398385A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Antibodies against interleukin-22
US20240254224A1 (en) 2021-05-03 2024-08-01 UCB Biopharma SRL Antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN113855807A (zh) * 2021-10-25 2021-12-31 孙良丹 一种试剂在制备治疗/抑制银屑病药物中的应用
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB129105A (en) 1918-07-02 1919-07-02 Alfred George Hubble Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels.
EP0569687B1 (en) 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
EP0813423B1 (en) 1995-01-23 2002-07-03 Xenotech Incorporated Composition to inhibit osteolysis and metastasis
JPH09183799A (ja) * 1995-11-06 1997-07-15 Merck Patent Gmbh ヒト化モノクローナル抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
JP2004536605A (ja) * 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
ATE525397T1 (de) 2011-10-15
PL378412A1 (pl) 2006-04-03
EP1597282A2 (en) 2005-11-23
US7608694B2 (en) 2009-10-27
NO20054223D0 (no) 2005-09-12
CY1112507T1 (el) 2015-12-09
SI1597282T1 (sl) 2012-02-29
GB0303337D0 (en) 2003-03-19
AU2004210776A1 (en) 2004-08-26
PE20040947A1 (es) 2004-12-29
CA2515474A1 (en) 2004-08-26
US8465744B2 (en) 2013-06-18
CA2515474C (en) 2013-11-12
TW200505942A (en) 2005-02-16
BRPI0407233A (pt) 2006-01-31
JP4668896B2 (ja) 2011-04-13
JP2010246553A (ja) 2010-11-04
KR20050099509A (ko) 2005-10-13
JP2007515925A (ja) 2007-06-21
MXPA05007392A (es) 2005-09-12
DK1597282T3 (da) 2012-01-23
ES2373953T3 (es) 2012-02-10
AU2004210776B2 (en) 2011-04-07
CN1745103A (zh) 2006-03-08
US20060228358A1 (en) 2006-10-12
WO2004072116A3 (en) 2004-11-18
NO20054223L (no) 2005-11-08
US20100158913A1 (en) 2010-06-24
EP2287193A1 (en) 2011-02-23
IS8013A (is) 2005-09-07
WO2004072116A2 (en) 2004-08-26
ECSP056014A (es) 2006-01-27
CL2004000259A1 (es) 2005-04-15
EA200501286A1 (ru) 2006-02-24
EP1597282B1 (en) 2011-09-21
PT1597282E (pt) 2012-01-05

Similar Documents

Publication Publication Date Title
AR043159A1 (es) Moleculas de anticuerpos que tienen especificidad para il-1beta humana
AR128047A2 (es) Moléculas de anticuerpos que se unen a il-17a e il-17f
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
CO5631451A2 (es) Anticuerpo especifico para cd22 humano y composicion farmaceutica derivada
PE20070998A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-6-humana
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
GEP20074222B (en) Antibodies to cd40
AR084315A1 (es) Anticuerpos anti-notch1
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
PE20160999A1 (es) Metodos para administrar anticuerpos anti-tnf-alfa
DK1503794T3 (da) Behandlingsfremgangsmåder ved anvendelse af CTLA-4-antistoffer
PE20110797A1 (es) Anticuerpos anti mn
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20080214A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
PE20061166A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-17 humana
RU2014120629A (ru) Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
NO20026063D0 (no) Antistoffer mot human MCP-1
ES2545745T3 (es) Conjugados de transportador derivado de caliqueamicina
AR075849A1 (es) Moleculas de anticuerpos que tienen especificidad de union por il-13 humana
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
ES2570153T3 (es) Anticuerpos anti-C5aR con propiedades mejoradas

Legal Events

Date Code Title Description
FB Suspension of granting procedure